Published in J Clin Oncol on May 01, 1998
Sensitive, noninvasive detection of lymph node metastases. PLoS Med (2004) 1.07
Management of axillary lymph nodes in breast cancer: a national patterns of care study of 17,151 patients. Ann Surg (1999) 1.05
Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes. Int J Clin Oncol (2011) 0.85
Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. J Breast Cancer (2016) 0.85
The effects of ECE on the benefits of PMRT for breast cancer patients with positive axillary nodes. J Radiat Res (2013) 0.82
Breast-conserving surgery after neoadjuvant chemotherapy in patients with locally advanced cancer. Preliminary results. G Chir (2014) 0.78
Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer. J Breast Cancer (2016) 0.75
Prognostic significance of apex axillary invasion for locoregional recurrence and effect of postmastectomy radiotherapy on overall survival in node-positive breast cancer patients. World J Surg (2004) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol (1998) 11.84
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28
Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst (2000) 4.26
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat (1992) 3.63
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol (2005) 3.62
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med (1992) 3.55
Cathepsin D and prognosis in breast cancer. N Engl J Med (1990) 3.43
The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 3.34
HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol (1989) 2.96
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst (1999) 2.58
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Speech perception as a function of electrical stimulation rate: using the Nucleus 24 cochlear implant system. Ear Hear (2000) 2.51
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol (1993) 2.42
Evaluation of a new spectral peak coding strategy for the Nucleus 22 Channel Cochlear Implant System. Am J Otol (1994) 2.37
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res (1990) 2.14
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res (1985) 2.13
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer (2000) 2.05
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst (1992) 2.05
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
Breaking bad news about cancer: patients' preferences for communication. J Clin Oncol (2001) 2.00
Child-reported family and peer influences on fruit, juice and vegetable consumption: reliability and validity of measures. Health Educ Res (2001) 1.97
Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst (1993) 1.95
How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst (1990) 1.95
Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol (2000) 1.95
Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst (1995) 1.91
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 1.89
The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J (1994) 1.87
Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat (1998) 1.85
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol (1984) 1.84
Risk of pulmonary complications after elective abdominal surgery. Chest (1996) 1.84
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol (1995) 1.81
Effect of a la carte and snack bar foods at school on children's lunchtime intake of fruits and vegetables. J Am Diet Assoc (2000) 1.81
Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med (1983) 1.79
Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr (1994) 1.79
Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst (1994) 1.77
Epidemiology of an international outbreak of Salmonella agona. Lancet (1973) 1.76
Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. Am J Med Genet (1999) 1.76
DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer (1988) 1.75
Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ (1995) 1.75
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst (1999) 1.75
Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat (1992) 1.74
Heterogeneous expression of the lipocalin NGAL in primary breast cancers. Int J Cancer (1998) 1.72
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst (2001) 1.68
Intracochlear factors contributing to psychophysical percepts following cochlear implantation. Acta Otolaryngol (1998) 1.68
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol (1994) 1.67
Electrical stimulation of the auditory nerve: the effect of electrode position on neural excitation. Hear Res (1993) 1.66
Variation in speech perception scores among children with cochlear implants. Ear Hear (2001) 1.64
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol (2005) 1.63
Evaluation of methods for isolating Salmonella and Arizona organisms from pet turtles. Appl Microbiol (1974) 1.62
Clinical findings for a group of infants and young children with auditory neuropathy. Ear Hear (1999) 1.60
Changing distribution of primary cancers in the large bowel. JAMA (1977) 1.59
p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res (1993) 1.59
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet (1996) 1.58
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res (1988) 1.57
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem (1999) 1.57
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest (1989) 1.56
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol (1999) 1.55
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol (1992) 1.55
Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat (1987) 1.54
Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res (1997) 1.54
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res (1993) 1.54